| |
(DDW) Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide plus Peginterferon and Ribavirin in Naïve Patients with Chronic Hepatitis C Genotype 1 Infection: Final Report (24 wk SVR)
|
| |
| |
Reported by Jules Levin
DDW May 4 2010 Late Breaker
B.R. Bacon,1 M.L. Shiffman,2 J.K. Lim,3 A. Berman,4 V.K. Rustgi,5 E.B. Keeffe,6,7 and STEALTH C-3 Investigators
1St. Louis University Medical Center, St. Louis, MO, 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, 3Yale University Medical Center, New Haven, CT, 4Florida Center for Gastroenterology, Largo, FL, 5Georgetown University Medical Center, Washington, DC, and 6Romark Institute for Medical Research, Tampa, FL, USA and 7Stanford University Medical Center, Stanford, CA, USA
|
|
| |
| |
|
|
|
